Caladrius

Caladrius Biosciences, Inc. (formerly NeoStem) is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s subsidiary, PCT, is a development and manufacturing partner exclusively focused on the cell therapy industry. PCT provides a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage, and distribution, as well as expert consulting and regulatory support.

Company Growth (employees)
Type
Public
HQ
Bernards, US
Founded
2006
Size (employees)
209 (est)
Caladrius was founded in 2006 and is headquartered in Bernards, US

Caladrius Office Locations

Caladrius has offices in Bernards and New York
Bernards, US (HQ)
4th Floor 106 Allen Rd
New York, US
350 420 Lexington Ave

Caladrius Financials and Metrics

Caladrius Financials

Caladrius's revenue was reported to be $7.9 m in Q1, 2017
USD

Revenue (Q1, 2017)

7.9 m

Gross profit (Q1, 2017)

(119.6 k)

Gross profit margin (Q1, 2017), %

(2%)

Net income (Q1, 2017)

(9.8 m)

EBIT (Q1, 2017)

(9.5 m)

Market capitalization (02-Oct-2017)

34.4 m

Closing share price (02-Oct-2017)

3.6

Cash (31-Mar-2017)

12 m
Caladrius's current market capitalization is $34.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

14.7 m17.9 m22.5 m35.3 m

Revenue growth, %

22%25%57%

Cost of goods sold

12.9 m15.7 m20.2 m31.1 m

Gross profit

1.7 m2.3 m2.3 m4.1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

4.5 m4.1 m3.2 m5.9 m5.9 m7.5 m8.3 m9.3 m7.9 m

Cost of goods sold

3.7 m4 m3.4 m5.8 m4.8 m6.2 m7.1 m8.6 m8 m

Gross profit

811.6 k105.4 k(196.3 k)68.2 k1.1 m1.3 m1.2 m706.3 k(119.6 k)

Gross profit Margin, %

18%3%(6%)1%18%17%15%8%(2%)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

46.1 m19.2 m20.3 m14.7 m

Inventories

1.3 m

Current Assets

50.8 m36.3 m29.3 m24.6 m

PP&E

12.8 m16 m17.1 m17.1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

32.9 m32.1 m19.1 m36.2 m24 m25.4 m17.7 m18.6 m12 m

Inventories

2 m2.1 m

Current Assets

40.9 m41.4 m29 m47.5 m38.5 m35.6 m29.3 m30 m21.9 m

PP&E

15.6 m15.7 m15.9 m16.8 m17.1 m16.9 m17 m17.1 m16.8 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(39.5 m)(55.5 m)(81 m)(33.3 m)

Depreciation and Amortization

1.6 m2.2 m2.7 m2.7 m

Accounts Receivable

(573 k)(1.2 m)545.2 k(325.6 k)

Inventories

(758.8 k)(2.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(26.6 m)(43.8 m)(19.2 m)(36.4 m)(47.8 m)(12 m)(19.9 m)(27.2 m)(9.8 m)

Depreciation and Amortization

987.7 k1.6 m604.4 k1.3 m1.9 m737.2 k1.4 m2.1 m655.3 k

Accounts Receivable

(602.1 k)(177.2 k)1.1 m1.8 m815.2 k(46.7 k)(326.4 k)(1.7 m)(277 k)

Inventories

(762.8 k)(872.1 k)
USDY, 2017

Revenue/Employee

37.2 k

Financial Leverage

-24.6 x
Show all financial metrics

Caladrius Market Value History

Traffic Overview of Caladrius

Caladrius Online and Social Media Presence

Caladrius Company Life and Culture

You may also be interested in